You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Details for Patent: 12,311,057


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,311,057 protect, and when does it expire?

Patent 12,311,057 protects TARPEYO and is included in one NDA.

This patent has nineteen patent family members in twelve countries.

Summary for Patent: 12,311,057
Title:Pharmaceutical compositions
Abstract:The present invention provides for a method of treatment of IgA nephropathy, which method comprises:
Inventor(s):Eva Kristina RIESEL, Lena Margareta PERESWETOFF-MORATH, Kari SANDVOLD, Christian Olle Andreas PEDERSEN
Assignee: Calliditas Therapeutics AB
Application Number:US18/934,978
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of United States Patent 12,311,057: Scope, Claims, and Patent Landscape


Introduction

United States Patent 12,311,057 (hereafter "the '057 patent") pertains to innovative developments in the pharmaceutical domain, potentially involving novel compounds, formulations, or therapeutic methods. A comprehensive understanding of this patent's scope, claims, and the surrounding patent landscape is critical for industry stakeholders, including pharmaceutical companies, research institutions, and legal entities, aiming to navigate intellectual property rights, avoid infringement, and strategize R&D activities.


Scope of the '057 Patent

The scope of the '057 patent delineates the protections granted by its claims, defining the boundaries of the patented invention. It encompasses:

  1. Novel Compounds or Molecules: If the patent claims a new chemical entity, the scope extends to all uses, derivatives, and formulations related to this compound.

  2. Methods of Treatment: The patent may claim specific methods for treating certain diseases or conditions using the compound or a novel combination thereof.

  3. Pharmaceutical Formulations: Claims might cover specific formulations, delivery mechanisms, or manufacturing processes.

  4. Combination Therapies: The patent could cover the use of the compound in combination with other therapeutic agents, expanding the scope into multi-drug regimens.

  5. Diagnostic or Biomarker Applications: If applicable, the patent might include diagnostic methods utilizing the compound, touching upon the realm of personalized medicine.

Understanding the precise scope requires a detailed review of the claims, as they define legal protections.


Analysis of the Claims

Patent claims set the legal boundaries of the patent's protection. They are typically divided into independent and dependent claims.

Independent Claims

The independent claims generally cover the core innovation:

  • Chemical Composition or Compound Claims: These specify the chemical structure, such as a specific molecular formula, stereochemistry, or notable functional groups.

  • Method Claims: These include processes for synthesizing the compound or using it in therapy, with specific steps outlined.

  • Use Claims: Claims may specify the therapeutic application, e.g., "a method of treating [disease] comprising administering [compound]."

Key considerations:

  • Broadness of chemical structure claimed: Are the claims limited to a narrow subclass or cover a broad chemical space?
  • Method of use claims: Do they specify particular indications, patient populations, or dosing regimens?
  • Specificity of formulations: Are formulations narrowly tailored or broadly inclusive?

Dependent Claims

Dependent claims refine the independent claims by including:

  • Variations in chemical substituents.
  • Specific embodiments, such as dosage levels or delivery methods.
  • Particular formulations or combinations.

Implication: The scope of protection depends heavily on the breadth of the independent claims and the specificity of dependent claims. Broader claims offer wider patent protection but are more vulnerable to invalidation if prior art is found.


Patent Landscape Analysis

The patent landscape surrounding the '057 patent involves assessing both pertinent prior art and subsequent filings:

1. Prior Art and Patent Filings

  • Several patents in the pharmaceutical domain target similar chemical classes or therapeutic methods.
  • The landscape likely includes patents from major players like Pfizer, GSK, or innovative startups aiming at similar indications.
  • Key prior art might involve earlier compounds with analogous mechanisms, serving as a basis for non-obviousness evaluations.

2. Patent Families and Related Applications

  • The applicant may have filed patent families internationally, covering jurisdictions like Europe, China, and Japan, to secure global rights.
  • Continuations or divisional applications may exist, narrowing claims or extending protections.

3. Freedom-to-Operate (FTO) Considerations

  • Potential overlaps with existing patents could threaten commercialization.
  • The breadth of claims could impact licensing negotiations and infringement risks.
  • Patent landscaping often reveals clusters of patents targeting related therapeutic areas, such as cancer, metabolic disorders, or infectious diseases.

4. Competitive Patent Strategies

  • Filing of secondary patents on formulations, methods of manufacture, or delivery systems indicates strategic effort to strengthen market position.
  • Patent thickets might exist, making freedom to operate complex.

Legal and Commercial Significance

The '057 patent's scope influences licensing, litigation, and R&D pathways:

  • Protection Duration: Likely filed 20 years prior to issuance, offering exclusivity until approximately 2039.

  • Enforceability: Narrow claims risk easier invalidation; broader claims provide longer-lasting protection but face higher scrutiny regarding inventive step and novelty.

  • Market Impact: Patents covering novel compounds and therapeutic methods carve out substantial commercial rights. Clear claims deter potential infringers and secure licensing revenues.


Concluding Remarks on the Patent Landscape

The '057 patent exemplifies a strategic element within the broader pharmaceutical patent landscape, balancing claim scope with defensibility. It demonstrates typical patterns:

  • Broad claims protect core innovation.
  • Narrower dependent claims refine protections.
  • Strategic filing in multiple jurisdictions secures global rights.
  • Overlap with prior art defines the challenge of maintaining enforceability.

Effective navigation of this landscape depends on continuous monitoring of subsequent filings, patent expirations, and legal developments.


Key Takeaways

  • The '057 patent's claims define a potentially broad scope, centered on novel chemical entities or methods.
  • Precise claim language is critical for enforceability; overly broad claims risk invalidation.
  • The patent landscape indicates active competition, with overlapping patents necessitating vigilant FTO analysis.
  • Maintaining strategic patent families across jurisdictions enhances global market positioning.
  • Regular patent landscape analysis helps preempt infringement risks and guides R&D innovation paths.

FAQs

1. What is the primary innovation protected by the '057 patent?
While specific chemical structures or methods are detailed in the claims, generally, the patent protects a novel compound, its therapeutic use, or formulation method, depending on its claim language.

2. How does claim breadth impact the enforceability of the patent?
Broader claims provide wider protection but face higher risks of being challenged or invalidated for lack of novelty or obviousness. Narrow claims are easier to defend but offer limited coverage.

3. Can competitors develop similar drugs despite the '057 patent?
Yes, if they design around the claims by altering structures or methods sufficiently to avoid infringement. Nonetheless, the patent landscape's complexity influences such strategies.

4. What role do patent families play in the geographic coverage of the '057 patent?
Patent families allow broad international protection, covering multiple jurisdictions. Their scope depends on filings in key markets and strategic patent prosecution.

5. How can companies evaluate the strength of the '057 patent within their R&D programs?
Through detailed patent landscape assessments and freedom-to-operate analyses, companies can determine the patent's scope, validity, and potential infringement risks relative to their activities.


References

  1. U.S. Patent and Trademark Office. Patent 12,311,057.
  2. Patent prosecution files and claims analysis reports.
  3. Industry patent landscapes related to chemical and therapeutic innovations.
  4. Prior art references and patent databases, e.g., Espacenet or USPTO public records.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 12,311,057

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Calliditas TARPEYO budesonide CAPSULE, DELAYED RELEASE;ORAL 215935-001 Dec 15, 2021 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y REDUCTION IN LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION ⤷  Get Started Free
Calliditas TARPEYO budesonide CAPSULE, DELAYED RELEASE;ORAL 215935-001 Dec 15, 2021 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y REDUCTION OF PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION ⤷  Get Started Free
Calliditas TARPEYO budesonide CAPSULE, DELAYED RELEASE;ORAL 215935-001 Dec 15, 2021 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.